# PsilOCD: A Pharmacological-Challenge Feasibility Study

> **NCT06258031** · PHASE1 · COMPLETED · sponsor: **Imperial College London** · enrollment: 19 (actual)

## Conditions studied

- Obsessive-Compulsive Disorder

## Interventions

- **DRUG:** Psilocybin (COMP360)

## Key facts

- **NCT ID:** NCT06258031
- **Lead sponsor:** Imperial College London
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-28
- **Primary completion:** 2024-06-28
- **Final completion:** 2024-07-24
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2024-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06258031

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06258031, "PsilOCD: A Pharmacological-Challenge Feasibility Study". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT06258031. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*